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Abstract. This paper proposes data mining techniques to model the return on investment from 
various types of promotional spending to market a drug and then uses the model to draw 
conclusions on how the pharmaceutical industry might go about allocating marketing 
expenditures in a more efficient manner, potentially reducing costs to the consumer.   
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Optimization of the marketing mix in the health care industry 
 
This paper proposes data mining techniques to model the return on investment from various 
types of promotional spending to market a drug and then uses the model to draw conclusions 
on how the pharmaceutical industry might go about allocating marketing expenditures in a more 
efficient manner, potentially reducing costs to the consumer.  The main contributions of the 
paper are twofold. First, it demonstrates how to undertake a media mix optimization process in 
the pharmaceutical context and carry it through from the beginning to the end. Second, the use 
of Directed Acyclic Graphs (DAGs) to help unravel the effects of various marketing media on 
sales volume, notably direct and indirect effects, is proposed.   
 
Introduction; current best practice in the pharmaceutical industry 
The matter of marketing expenditures by the pharmaceutical industry continues to attract 
considerable attention (see editorial by Mukherjee, 2012 and the introduction by Crié and 
Chebat to the special issue in the Journal of Business Research on health marketing, 2013), 
particularly at a time when health care costs are coming under tightened scrutiny. In this 
context, while marketing expenditures in the pharmaceutical industry have continued to decline 
(Eyeforpharma, 2014), concerns remain about the proportion of such expenditures relative to 
that of Research and Development (Pew 2013), and about direct-to-consumer (DTC) marketing 
programs, legal only in the United States and New Zealand (Liang and Mackey 2011).  
Marketing efforts in the pharmaceutical industry can be grouped into two categories:  1) direct-
to-consumer (DTC) advertising such as TV, print, internet ads as well as Customer Relationship 
Management (CRM) programs, and 2) professional or direct-to-physician (DTP) promotions 
including samples, details, journal advertising, professional interactions, and non-personal 
promotions (NPP).  Most of the market mix analyses in the industry focus on measuring the 
effects of the different DTC advertising channels after controlling for DTP promotions.  These 
analyses are usually performed by creating a control group of physicians in Designated Market 
Areas (DMAs, geographic areas defined by the Nielsen Media Research Company as a group 
of counties that make up a particular television market) or other geographic areas matched to a 
test group with identical levels of DTP promotions and physician characteristics.  The test and 
control groups have varying levels of DTC activities; this allows for the measurement of the 
effect of the different DTC efforts.   
New product launches typically utilize market mix models to simulate potential outcomes 
(market volume, ROI, etc.) under different media spending scenarios.  These models 
incorporate intermediate outcomes such as brand awareness and other consumer behavior that 
result from consumers asking their doctor about the brand and subsequently filling prescription 
for this brand.     
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We next review pertinent recent literature and outline the objectives and contributions of this 
paper. 
 
Review of recent literature 
While the issue of optimizing marketing mixes has been of interest for many years in the 
marketing literature, relatively little such published work is dedicated to the health care industry. 
Of particular relevance to this paper, albeit in another industry (tourism), is the work by Wolfe 
and Crotts (2011) where a marketing mix methodology is applied to ticket sales for a museum.  
In general the literature in health care marketing makes the point that decisions on 
pharmaceutical marketing expenditures are often of a qualitative or policy nature, but that it is in 
fact important to quantitatively link marketing expenditures and new prescription volume, since a 
more optimal allocation of expenditures would lead to savings that could be expected to 
decrease the price of drugs for patients. 
Past work has attempted to address the issue of correlated predictors and the problem of a 
suitable choice of a set of predictors for the number of new prescriptions for a drug, or any other 
yield dependent variable.  Lim and Kirikoshi (2008) and Lim, Kirikoshi and Okano (2008) 
propose to use a genetic algorithm (with the predictive power of a model as an objective 
function) to help select a suitable set of predictors, in combination with a neural net, or a partial 
least squares regression.  The models perform well, but one issue that remains to be addressed 
is of how to operationalize the model for marketing expenditure allocation, when, for example, 
some coefficients are negative. In many cases, practitioners faced with inconvenient negative 
coefficients are forced to ignore them. However, negative coefficients can and sometimes do 
represent reality; we will return to this issue later in the paper.  
Manchanda et al. (2008) propose a model which takes into account the fact that the level of 
marketing-mix variables is often set with at least partial a-priori knowledge of the likely level of 
response for each variable, and find that this approach results in a more precise estimation of 
response parameters.  They also find that physicians are often not detailed optimally, but that 
high-volume physicians are detailed to a greater extent than low-volume physicians without 
regard to responsiveness.  The work by Singh (2008) proposes a conceptual model that 
incorporates several aspects of the network created by physician-salesperson dyads.  
More recently, Huber et al. (2012) have constructed models, applicable to different categories of 
Over The Counter (OTC) products, which help to identify drivers of product sales in the OTC 
market. Gönül and Carter (2012) construct a model of physician prescribing volume of older 
versus newer drugs and confirm the importance of sampling and detailing.  
It is useful to note, since markets do differ across countries, that the context discussed in this 
paper is that of pharmaceutical marketing in the United States. In particular, from a research 
point of view, data availability varies across countries. Obtaining data for research about 
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marketing pharmaceutical expenditures is notoriously difficult in the United States, and can 
occur almost exclusively in the context of collaborations between academics and practitioners 
and by of course masking all identifiers of drugs, patients, physicians and even pharmaceutical 
organizations involved.     
In summary, past literature has identified main drivers of prescribing behavior in a number of 
pharmaceutical industry cases, and preliminary marketing mix models have been constructed.  
However, the issue of correlated predictors remains a challenge, as well as the 
operationalization of media mix models in the pharmaceutical context. In order to address this 
gap, this paper makes the following twofold contributions: 
1. For the first time in the literature (to the best of our knowledge) we demonstrate how to 
undertake a media mix optimization process and carry it through from the beginning to 
the end; to achieve this goal, synthetic data are employed. 
2. We propose the use of Directed Acyclic Graphs (DAGs) to help unravel the effects of 
various marketing media on sales volume, notably direct and indirect effects. 
 
We now outline the two main phases which are typically included in a media mix analysis and, 
after providing details about the synthetic dataset used here, we describe and implement each 
step of the two phases in a prototype marketing mix process.  
 
Modeling approach 
The approach to optimizing the marketing mix for a product typically proceeds in the following 
two phases: 
Phase 1 
 
A model is built for the output variable (typically new prescriptions in a given time period) in 
terms of a number of relevant independent variables. Phase 1 corresponds to the central and 
upper sections of Figure 1.  
Phase 2 
 
Once a satisfactory model has been constructed, the model is employed to evaluate the 
contribution of each marketing activity to the new prescriptions. The objective is to obtain output 
such as obtained in Figure 2, although the marketing components will tend to differ in a 
pharmaceutical context. This step corresponds to the central lower part of Figure 1. 
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Figure 1: Framework for Marketing ROI assessment and optimization 
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Figure 2: Typical output from a marketing mix modeling analysis (extracted from Wikipedia, 
Marketing Mix Modeling, 2014) 
 
 
In order to illustrate the methods proposed in this paper, we describe below a “Prototype 
modeling approach for Phases 1 and 2” on the basis of synthetic data. We next introduce the 
data used to that effect. 
 
Data 
 
Using the Stata statistical software, we generate synthetic data simulated from the correlation 
matrix and summary statistics for 12 variables in Lim et al. (2008). The variables include, over a 
period of 71 months, the number of new prescriptions (nrx) and eleven variables related to 
various aspects of different advertising activities (see Table 1). In Lim et al. (2008) the dataset 
was obtained from a marketing consultant and concerns an antibiotic drug in the United States. 
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Complete information about the variables can be found in Lim et al. (2008), but we reproduce 
the definitions given in that paper here for the sake of completeness and convenience.  As 
defined by Lim et al. (2008): 
“Contacts” (CON) is a product-level report of promotional actions that is provided to 
physicians and “calls” (CAL) measures the total number of visits made by 
pharmaceutical representatives to physicians. A CON can be a full product discussion 
with a physician, a drug fair set up at the hospital for physicians or a delivery of a 
product sample. Several products may be discussed during a single call, resulting in the 
possibility of multiple CONs in a CAL. “Cost of contacts” (COC) includes the costs 
associated with detailing of representatives that are directed to physicians. “Cost per 
contact” (CPC) is an estimate of cost per contact whereas “minutes” (MIN) is the 
projected sum of time spent with physicians. In a broad sense we interpret CPC as the 
quality of CON. This is a rough approximation that accounts for the difficulty and 
complexity of assessing the physician’s overall impression of the representative’s visits. 
“Journal advertising spending” (JAS) captures the expenditure of advertising in medical 
journals. “Ads” (ADS) measures the number of different layouts of product 
advertisements in medical journals. If the same ad appears in two journals, it is counted 
twice. “Ad pages circulated” (ADP) represents the number of total ad pages circulated in 
journals for a particular product. “Sample” (SAM) shows the projected volume of a 
product provided as samples to physicians whereas “extended units samples” (EUS) 
measures the amount of a product sampled as the number of packages multiplied by the 
size of the package in tablets, capsules, milliliters, etc. EUS is appropriate for use when 
the products being compared are similar in terms of dosage form. “Retail value of 
sample” (RVS) represents the retail value of SAM. “New prescription volume” (NRx) 
represents the count of new prescriptions dispensed by pharmacists. 
We note that in addition to data on the brand of antibiotic (referred to as A) simulated from the 
statistical summaries in Lim et al. (2008), it would be potentially possible to simulate data from 
the statistical summaries on three other brands B, D and D also covered in the work by Lim et 
al. (2008).   
Analysis: phase 1 
As is readily visible on Figure 3, a major issue when attempting to build a model for the number 
of new prescriptions in terms of the eleven predictors is that a high level of correlation exists 
among the predictors. For example, contacts and cost of contacts are highly correlated as one 
might expect. Contacts, calls and cost of contacts are highly correlated to the retail value of 
samples.   
The first row of the matrix scatter plot graphs the dependent variable nrx in terms of the eleven 
predictors; a positive linear relationship emerges between nrx and each predictor except for cpc 
(Cost per Contact) where that relationship is negative. 
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Table 1: List of synthetic variables (following Lim, Kirikoshi and Okano (2008)) and summary 
statistics 
 N Minimum Maximum Mean Std. Deviation 
Con (Contacts) 71 7657.00 99188.00 54113.88 21606.72 
Cal (Calls) 71 5361.00 77657.00 38964.52 17162.88 
Coc (Cost of Contacts) 71 737297.00 8041793.00 4357317.52 1740648.34 
Cpc (Cost per Contact) 71 62.00 114.00 87.92 10.67 
Min (Minutes) 71 32682.00 334945.00 182602.33 72862.46 
Jas (Journal Advertising Spending) 71 .00 486943.00 217926.80 112177.79 
Ads (Ads) 71 .00 30.00 14.12 6.57 
Adp (Ad Pages Circulated) 71 .00 82.00 39.16 20.22 
Sam (Samples) 71 615.00 2614948.00 1094355.12 627396.75 
Eus (Extended Unit Samples) 71 1230.00 8204439.00 3556610.79 1743431.60 
Rvs (Retail Value of Sample) 71 6660.00 18502700.00 8582259.60 3820827.20 
Nrx (New Prescription Volume) 71 84895.00 2466777.00 1080544.09 512578.60 
 
If we attempt to run a linear regression for nrx in terms of the eleven predictors, several 
variables fail to be significant and the negative coefficients for some of the variables might be 
considered counter-intuitive (Table 2). A stepwise regression for nrx (Table 3) yields a negative 
coefficient for jas and includes a small number of significant predictors.  
One option would be to remove jas and evaluate the resulting model; this yields an R-square of 
.910, not a very large loss from the value .919, and the coefficients of the remaining three 
variables are positive and significant. However, and this is a matter that would need to be 
elucidated from domain knowledge of the data, the negative sign could in fact represent a 
reality.  We are aware of an interesting case where a negative sign appeared in a similar 
marketing mix, but this time in the banking industry. It transpired that all coefficients were 
positive in what looked like a sensible linear regression model, except that of newspaper 
advertising expenditures. A more careful examination revealed that interest rates were higher 
for the bank under consideration than for competitors and that those rates were published in the 
same newspapers!   
 Table 2: Linear regression of nrx in terms of all eleven predictors (R-square=.931) 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
1 
(Constant) 1296725.732 522210.488  2.483 .016 
con -31.255 14.707 -1.318 -2.125 .038 
cal 12.363 16.948 .414 .729 .469 
coc .190 .119 .646 1.595 .116 
cpc -11301.270 4710.481 -.235 -2.399 .020 
min 1.228 1.648 .174 .745 .459 
jas -1.556 .583 -.341 -2.668 .010 
ads 33979.885 14621.334 .435 2.324 .024 
adp 2713.728 5320.917 .107 .510 .612 
sam .480 .239 .588 2.009 .049 
eus -.137 .077 -.465 -1.782 .080 
rvs .075 .025 .563 3.034 .004 
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Figure 3: Matrix scatter plot for twelve synthetic variables   
 
Table 3: Stepwise linear regression results for nrx (R-square=.919) 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. 
B Std. Error Beta 
1 
(Constant) 22055.430 52669.622  .419 .677 
jas -1.214 .450 -.266 -2.699 .009 
ads 33026.816 9082.479 .423 3.636 .001 
sam .228 .088 .279 2.602 .011 
rvs .071 .014 .527 5.036 .000 
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A potentially better approach is to extract uncorrelated factors to explain as large as possible an 
amount of variability in the eleven predictors. A solution with two factors, rotated with a 
quartimax rotation, explains 91.3% of the total variability in the predictors and is presented in 
Table 4. 
 
Table 4: Factor analysis of all eleven predictors 
Component Initial Eigenvalues Extraction Sums of Squared Loadings Rotation Sums of Squared Loadings 
 
Total 
% of 
Variance Cumulative % Total % of Variance Cumulative % Total 
% of 
Variance 
Cumulative 
% 
 
1 8.487 77.153 77.153 8.487 77.153 77.153 7.938 72.160 72.160 
2 1.611 14.649 91.801 1.611 14.649 91.801 2.106 19.148 91.308 
3 .476 4.325 96.126 .476 4.325 96.126 .530 4.819 96.126 
4 .220 2.001 98.127       
5 .097 .885 99.012       
6 .051 .467 99.479       
7 .022 .198 99.677       
8 .021 .192 99.868       
9 .009 .083 99.951       
10 .003 .031 99.982       
11 .002 .018 100.000       
 
 
Table 5: Loadings of each predictor onto each rotated factor 
 
 
Component 
1 2 
con .988 .046 
cal .984 .053 
coc .964 .066 
cpc -.768 .098 
min .979 .031 
jas .437 .873 
ads .594 .787 
adp .539 .828 
sam .958 .169 
eus .921 .193 
rvs .951 .137 
Extraction Method: Principal Component Analysis.  
 Rotation Method: Quartimax with Kaiser 
Normalization. 
a. Rotation converged in 3 iterations. 
 
Table 5 reveals that the first factor seems to represent activities directly targeted to physicians, 
while the second factor represents more general advertising activities.  Table 6 displays the 
coefficients for the Z score of each predictor needed to compute the factors, and Table 7 
presents the results of a regression of nrx on the two factors (R-square = .885). 
One can then extract a formula for the estimated new prescription volume in terms of the Z 
scores of the predictors (and ultimately in terms of the predictors themselves, of course) and 
use an optimization process, here a simple linear programming application, to find the optimal 
value of the Z scores under some constraints, such as total budget, etc. For illustrative 
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purposes, we set the lower limit at -2 and the upper limit at 4 for each Z score, with an upper 
limit of 30 for the sum of all Z scores, and obtain the results in Table 8.  
 
Table 6: Coefficients to compute each factor in terms of the Z-scores of the predictors 
 
Component 
1 2 
con .151 -.109 
cal .149 -.105 
coc .144 -.094 
cpc -.135 .162 
min .151 -.117 
jas -.051 .446 
ads -.014 .375 
adp -.028 .406 
sam .129 -.034 
eus .120 -.015 
rvs .132 -.051 
Extraction Method: Principal Component 
Analysis.  
 Rotation Method: Quartimax with Kaiser 
Normalization.  
 Component Scores. 
 
Table 7: Linear regression of nrx in terms of the two factors 
Model Summary 
Model R R Square Adjusted R 
Square 
Std. Error of the 
Estimate 
 
1 .941
a
 .885 .882 1.76432E5 
Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) 1080544.093 20938.592  51.605 .000 
Factor1 470291.077 21087.623 .918 22.302 .000 
Factor2 106415.943 21087.623 .208 5.046 .000 
a. Dependent Variable: nrx 
 
Two remarks are in order. First, while we have used a factor analysis on the predictors, and 
then used the factors in a regression analysis for new prescriptions, we could also use a Partial 
Least Squares regression, which will attempt to extract factors which explain a satisfactory 
proportion of the variability in the predictors as well as in the new prescriptions.  Such an 
analysis performed on the synthetic data yields similar results to those above, but with a slightly 
smaller of proportion of the variability in the predictors explained (90.5%) and a bit higher a 
proportion of variability in new prescription explained (89.3%). Second, our analysis does not 
take into account any correlation in the errors of the regression model.  The synthetic data were 
created without such correlation, but it is very likely that error correlation exists in real data, and 
would need to be taken into account, for example by modeling the errors as autoregressive or 
even ARMA (Auto Regressive Moving Average).   
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Analysis: phase 2 
Table 8 reveals that an optimal mix would set the variables con, cal,coc, min, ads, sam, eus and 
rvs at their maximum levels, the variables cpc and jas at their minimum level, and the variable 
adp at a high but not maximum level (2 standard deviations above its mean). 
Table 8: Optimization of predictors using linear programming 
Variable Coefficient of Z Score of variable 
in objective function 
Optimal Z 
Score 
Contribution of variable 
to objective function 
Lower limit Upper limit 
con 59167.95 4 236671.81 -2 4 
cal 58912.58 4 235650.32 -2 4 
coc 57713.02 4 230852.08 -2 4 
cpc -46433.24 -2 92866.49 -2 4 
min 58693.49 4 234773.95 -2 4 
jas 23596.74 -2 -47193.47 -2 4 
ads 33295.52 4 133182.09 -2 4 
adp 29855.06 2 59710.12 -2 4 
sam 56987.67 4 227950.67 -2 4 
eus 54746.69 4 218986.76 -2 4 
rvs 56685.92 4 226743.68 -2 4 
      
   Objective function   
 Constraint on the sum of Z 
Scores for all variables 
30 1850194.49   
 
Another approach to unraveling the effects of correlated predictors: Directed Acyclic 
Graphs  
Another approach to help unravel the effects of correlated predictors on the new prescription 
volume is the construction of a Directed Acyclic Graph (DAG), followed by the estimation of a 
structural equation model based on directional links indicated by the DAG. This approach, which 
relies on the seminal work by Pearl (2009) has been known to work well for the purpose of 
illuminating direct and indirect effects, the size of which can then be estimated once a 
hypothetical model is obtained from the DAG (see for example work by Bessler, 2001, 2002).  
This is particularly useful in cases, such as here, where theory is scant or non-existent as a 
guide as to which predictors drive new prescriptions.  To give an idea of how this approach 
works, we use a modified PC (Partial Correlation) algorithm (PC Pattern) from the Tetrad IV 
package (The Tetrad Project 2014) to construct a DAG from the synthetic data, with the 
resulting graph displayed in Figure 4. We also give a brief description of the PC algorithm. 
A few interesting features emerge from Figure 4.  Samples seem to have an effect on new 
prescriptions, but indirectly, via their retail value.  The cost per contact has an effect on the 
number of contacts, which seems sensible.  We note that the PC algorithm typically yields not 
one but a class of directed acyclic graphs which are compatible with the data.  When a directed 
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arrow appears on the graph, this means that the direction was the same in all graphs generated 
by the algorithm. When this is not the case, the direction of the link is ambiguous and a link 
appears without arrows, as for example between sam and eus.  The only variable which links 
directly into nrx is rvs, the retail value of samples.    
Figure 4: Directed Acyclic Graph for twelve synthetic variables   
 
Brief description of the PC (Partial Correlation) algorithm 
The PC algorithm works essentially as follows. First, a complete undirected graph is created 
with each variable corresponding to a vertex.  Then edges are removed in pairs with variables 
which are independent, either unconditionally or conditionally on a subset of the remaining 
variables.  Independence is tested with standard correlation tests (for continuous data assumed 
to be multivariate normal) or by using a test of independence in contingency tables (for 
categorical data).  Note that Tetrad allows for either continuous data, or categorical data, but not 
a mixture of both types of data, unless the user provides a-priori information on which pairs of 
variables are independent conditionally on other variables. For a discussion of Tetrad and other 
acyclic graph software packages, see Haughton, Kamis and Scholten, 2006.  
 
In order to orient the surviving links, the PC algorithm proceeds as follows: for each triplet X, Y, 
Z such that both pairs X, Y and Y, Z are linked but the pair X, Z is not linked,  if Y does not 
appear in any set of variables which when conditioned upon makes X and Z independent, then 
the triplet X, Y, Z is oriented   X→ Y← Z, in effect making Y a collider.  This makes sense since 
such an orientation implies that  X and Z are dependent given Y.  Once all such colliders are 
identified, the algorithm proceeds like so: if X→ Y, Y and Z are linked and X and Z are not 
linked, and if there is no arrowhead at Y from Z, then Y, Z is oriented as Y→ Z. Such an 
orientation implies that X and Z are independent given Y. Appendix B of the Tetrad III user 
manual (The Tetrad Project 2010) explains how the algorithm unfolds on a particular example. 
See also Haughton and Haughton (2011), chapter 5, for an introduction to directed acyclic 
graphs with examples. 
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It is important to note that Directed Acyclic Graphs can infer causality as defined in Pearl (2009), 
but under very restrictive assumptions which tend not to be satisfied in many cases.  So one 
would not want to claim any hope of getting definite causality statements out of this analysis; 
however what is obtained is a better understanding of which effects might be direct effects and 
which might be indirect.    
 
Discussion 
This paper has proposed a road map which should be helpful to researchers and practitioners 
involved in media mix modeling. The synthetic data on which our analyses rely relate to the 
marketing of a drug, but the methodology can be used in contexts other that health care as well. 
 
The issue of negative coefficients in media mix models is one which, while unmentioned in the 
literature, is quite an important practical problem. In many real-life situations, negative 
coefficients are either ignored, or their sign ignored, when establishing the importance of each 
component. We have illustrated the fact that the key issue with negative coefficients is whether 
they arise because of multi-collinearity in the model or because of the genuine negative effect of 
a particular component. Discovering which of these two options holds is important.  
 
Many media mix models include expenditures which are quite highly correlated. Because the 
mechanism which yields new prescriptions or higher sales in general is likely to be quite 
complex, we have suggested in this paper that Directed Acyclic Graphs can be pressed into 
service to help unravel which expenditures are directly linked to new prescriptions and which 
expenditures might act via an intermediary variable. 
 
Several issues of interest remain for future work. One is the matter of the presence of 
competitor promotion expenditures when a few major competitors are present in a particular 
market. We suggest and investigate elsewhere (Haughton et al. 2013) that ignoring competing 
promotion activity in a media mix model could lead to biased results. Assuming that data on 
competing sales are available, it is possible to impute with good success the presence or 
absence of competitor promotional activity when two competitors are in place via the use of 
hidden Markov models (Haughton et al. 2013). More work remains to be done on situations with 
more than two main competitors, for example.    
 
It also would be very interesting to apply these techniques to a real life data set. The synthetic 
data set presented in this paper is very representative of data used in a media mix marketing 
effort for the marketing for a drug, but nevertheless, applying the methods to actual data would 
be very valuable. The difficulty here is the scarcity of such datasets available to researchers.   
 
In particular, a real life data set is very likely to include time series with auto-correlated 
variables. An interesting extension of this paper would be to adjust the methods to take into 
account auto-correlation in the errors of the media mix regression model.   
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Last but not least, the importance of word of mouth and viral marketing, notably via social 
networks, and in particular via social networks which are related to the medical profession, 
inclusive of co-publication networks, cannot be underestimated. The problem of how to combine 
social network data (on influential prescribers etc) with more traditional data used in media mix 
modeling is becoming quite pressing. Media mix models of the future will very probably need to 
incorporate social network components, since ignoring these components risks leading to 
biased results. A rather key challenge there is to link social network data to existing corporate 
databases used for targeting physicians and for building marketing programs.  
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